Introduction

In Italy, access to treatment for patients suffering from a rare disease is guaranteed through various legal instruments. The centralized procedure represents the standard access route; whenever an orphan drug has no marketing authorization, patient access is ensured through different early access schemes. One of these early access tools is the Law 326/2003, Article 48 (also known as 5% AIFA fund).

The Law 326/2003, Article 48, requires all pharmaceutical in the market the activity of 5% of the reimbursement schemes (i.e., companies' expenses), to be evaluated annually by the Scientific Institute for Pathway Analysis and Safety (AIFA). Furthermore, an economic evaluation is conducted to determine the economic impact of this fund.

The request for access to Fondo AIFA 5% is patient-specific and is submitted to the Italian Medicines Agency (AIFA) by a Reference Centre. The following documents are required in order to access the fund: a formal request, supported by scientific literature (if any) and a brief clinical report, including a description of the therapeutic plan for each patient. The application shall be submitted by specific information, such as: dose per treatment cycles, number of cycles and the price of the medicine.

The application is assessed by AIFA, which issues its opinion after the verification and composition of the requirements set out in the law. On the basis of the supporting documents submitted as a proof of costs incurred for the patient's treatment, AIFA reimburses the invoices submitted.

Objective

This study aims to assess AIFA's approach on requests related to inclusion in Fondo AIFA 5%, evaluating the novelty and the characteristic of applications submitted to AIFA and their evaluation by the Agency. Moreover, the economic impact of medicinal products included in Fondo AIFA 5% during the years was evaluated.

Methods

The drugs' panel was built by systematically reviewing the reports of the AIFA CTS meetings (“Area Pre-Autorizzazione”) published from January 2013 to September 2019, checking the number and characteristics of each drug under evaluation and analysing each single decision taken by the CTS.

For this reason, OMed reports provide information on the orphan drugs/rare disease early access tools, and consequently about the Law 326/2003, in the art. 48 (Fondo AIFA 5%) during the years was evaluated.

Results

- From 2013 to 2017, the CTS evaluated 69 applications. AIFA CTS approved 29/69 (42%) requests for access to Fondo AIFA 5%, regarding 11 drugs. 8/11 drugs approved (73%) had an Orphan Designation.
- Between these 29 requests the outcomes were as follows:
  - 14 were “positive” (48%),
  - 2 were positive but subordinate to the possible AIC (7%),
  - 1 was positive only for one of two patients (3%),
  - 8 were positive for limited period of time (28%),
  - 2 were positive only if patients are not eligible for the approved indication, not included in the compassionate use programme, and satisfy certain clinical characteristics (7%),
  - 2 were positive with subsequent CTS re-evaluation (7%).
- The Anatomical Therapeutic Chemical (ATC) code mainly represented the L (antineoplastic and immunomodulating agents) (50%) followed by the J (antineoplastic for systemic use) (20%). The R (respiratory system), B (blood and blood forming organs) and A (alimentary tract and metabolism) represent 10% for each.

We have also checked the last available OMed reports of 2013-2018, to check the economic impact of 326 Law on Fondo AIFA 5% during the years.

- 1 was applicable for the importation (2.5%),
- 2 were negative because the drug was authorized and available (7%),
- 2 were acknowledging (5%),
- 3 required further evaluation (7.5%),
- 2 had a pending EMA's decision (5%),
- 1 was under evaluation of patient's clinical data (5%).

There are no data available concerning requests made in the years 2018-2019, since the last available (i.e., published) CTS's decision refers to 2017.

We have also evaluated the changes in Fondo AIFA 5% both in terms of amount of this fund and in terms of expenditure related to medicinal products subject to the Law 326/2003. The OMed reports of 2013 - 2018 provided economic information on Fondo AIFA 5% and the economic impact of drugs included in Fondo AIFA 5%. Between 2013 and 2018 the fund was slowly growing, with the exception to 2015 when declined.

The economic impact (expenditure) of drugs included in Fondo AIFA 5% has increased considerably during the years: 183.382,00 € in 2013 (1%), 239.895,00 € in 2014 (2%), 1.108.530,00 € in 2015 (6%) and 13.465.742,00 € in 2017 (76%). No data for 2016 and 2018 were present in the OMed Report.

Conclusions

Fondo AIFA 5% is one of the early access schemes in Italy. The 50% of the fund is dedicated to the purchase of orphan drugs for the treatment of rare diseases or medicinal products for the treatment of serious conditions, which are not commercialized yet.

During 2013-2017 the AIFA CTS had evaluated 69 requests of access to Fondo AIFA 5%, approving 48% of them (no data about CTS evaluation was published after 2017). The approved drugs were mainly antineoplastic and immunomodulating agents (ATC-L1) (50%) followed by the antineoplastic for systemic use (ATC-J) (20%).

Moreover, the OMed Reports provided the economical data about the amount of the fund and its expenditure. The numbers show that the fund has been growing slowly during the years. Similarly, the number of drugs included in the fund (and therefore also the number of patients who have had access to these drugs) has increased, as well as the expenditure of the fund dedicated to these drugs.

Our data showed that Law 326/2003, Article 48, paragraph 19a, in 10 years has become a useful tool and its use significantly increased during the last years, showing AIFA's commitment to Italian patients.

References

- [Website]: https://www.aifa.gov.it/archivio?strutture=96918
- [Data]: https://www.aifa.gov.it/area-news
- [Data]: https://www.aifa.gov.it/area-news
- [Data]: https://www.aifa.gov.it/area-news

For further information: Please contact: Marialunga Prada – Head of Patient Access

Intesa Società Beneficenza - via del Tritone, 169 – 00187 Rome Italy – marialunga.prada@intesaita.it